Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.

Cancer science - 1 Apr 2023

Liu Ruiqi, Niu Yanling, Liu Chao, Zhang Xin, Zhang Jinku, Shi Min, Zou Wenbo, Gu Binbin, Zhu Honglin, Wang Danhua, Yuan Hongling, Li Wei, Zhao Dandan, Zheng Qiaosong, Liu Rong, Chen Weiping, Ma Tonghui, Zhang Yanqiao

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have become important treatment strategies, yet responses vary among patients and predictive biomarkers are urgently needed. Mutations in KMT2C and KMT2D lead to increased levels of genomic instability. Therefore, we aimed to examine whether KMT2C/D mutations might be a predictor of immunotherapeutic efficacy. Here, we investigated the associations of KMT2C/D loss-of-function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to CD8-Positive T-Lymphocytes

Share to Colorectal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36601880
DOI: 10.1111/cas.15716
PMCID: PMC10067420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.PMID 36601880Read ↗

<i>MLL4/KMT2D</i> mutations increase immune activity and predict therapy efficacy in colorectal cancerSemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Semantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinomaSemantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer.Semantic proximity Read ↗

Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.Semantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read ↗

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.